The importance of reducing cardiovascular risk in patients with type 2 diabetes
This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed. This eLearning module is intended for healthcare professionals.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
PC-GB-105238 September 2021
Disease-modifying anti-rheumatic drugs (DMARDS) guidelines: a focus on methotrexate guidance in clinical practice
Information intended for UK healthcare professionals only. This webinar was initiated and commissioned by Accord-UK Ltd and developed in partnership with Guidelines in Practice.
View Methofill® (methotrexate) pre-filled injector and pre-filled syringe prescribing information and adverse event reporting information here
View the Summary of Product Characteristics for Folic Acid 5mg Tablets; Legal Cat POM; NHS List price 90p
UK-02645
Date of preparation: September 2021
Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care
This promotional webinar has been initiated and commissioned by Boehringer Ingelheim Limited and organised in partnership with Guidelines in Practice.
View Trajenta® (linagliptin) prescribing and adverse events reporting information for:
Great Britain
Northern Ireland
PC-GB-103485 | July 2021
The importance of inhaler choice
Information intended for UK healthcare professionals only. This promotional webinar was commissioned and funded by Boehringer Ingelheim and developed in partnership with Guidelines in Practice.
View prescribing information here.
PC-GB-104812
Date of preparation: June 2021
Specialist support for your patients with cancer - Macmillan’s Support Line can help.
From clinical information to emotional support, and advice on money and work, the Macmillan Support Line will do whatever it takes to support your patients. Learn more here.
Cow’s Milk Allergy (CMA) and The Allergic March
This promotional animation has been commissioned and funded by Reckitt and developed in partnership with Guidelines in Practice.
RB-R-9342 November 2021
Animation on the decompensated cirrhosis care bundle—the first 24 hours
This animation has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines in Practice.
UKE-COR-NP-2100080 Date of preparation: October 2021
Prescribing a dipeptidyl peptidase-4 inhibitor in adults with type 2 diabetes and comorbidities
This animation has been commissioned and funded by Boehringer Ingelheim Limited and developed in partnership with Guidelines in Practice.
View Trajenta (linagliptin) adverse event reporting and prescribing information for Great Britain or Northern Ireland
PC-GB-105090 Date of preparation: October 2021
In conversation: barriers to implementation of the NHS restructure and future opportunities
In the final In conversation video on the NHS restructure, Dr Karen Kirkham and Dr Anthony Cunliffe explore barriers to the success of the changes
In conversation: potential benefits of the NHS restructure for practice and patients
In the second In conversation video on the NHS reorganisation, Dr Karen Kirkham and Dr Anthony Cunliffe talk about the emerging benefits of the changes
In conversation: specifics and context of the NHS restructure
In the first of a new series of In conversation videos, Dr Karen Kirkham and Dr Anthony Cunliffe discuss the details and backdrop of forthcoming changes to the NHS in England
Five things you need to know about… bronchiectasis
In the first of a new series of videos, Dr Kevin Gruffydd-Jones highlights five things you need to know about bronchiectasis
NICE guidance on respiratory conditions and COVID-19: 5-minute video
Dr Kevin Gruffydd-Jones highlights important things you need to know about managing respiratory conditions in a COVID-19 context
FERACCRU® (ferric maltol) 30 mg hard capsules
Information intended for UK healthcare professionals only. This formulary decision guide is promotional and was developed from content provided by Norgine Pharmaceuticals Limited in a format developed by Guidelines in Practice (contains promotional information).
View FERACCRU® (ferric maltol) prescribing information and adverse event reporting information here
UK-HAE-FER-2100127
Date of preparation: December 2021
Jardiance® (empagliflozin) film-coated tablets for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF)
This formulary decision guide was commissioned by the Boehringer Ingelheim and Lilly Alliance.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain and Northern Ireland.
PC-GB-105819 October 2021
Klisyri▼ (tirbanibulin) 10 mg/g ointment
This formulary decision guide was developed from content provided by Almirall Ltd in a format developed by Guidelines in Practice. It was commissioned by Almirall Ltd, who carried out full medical approval to ensure compliance with regulations.
View prescribing and adverse event reporting information
UK-KLI-2100017 | Date of preparation: October 2021
Sixmo®▼ (buprenorphine) 74.2 mg implant
Information intended for UK healthcare professionals only. This formulary decision guide was developed from content provided by Accord Healthcare Limited in a format developed by Guidelines in Practice.
View prescribing information and adverse event reporting information.
UK-03417
Date of preparation: October 2021
Ipinnia® XL (ropinirole hydrochloride) prolonged-release tablets
This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-IPN-13 Date of preparation: September 2021
Xaggitin XL (methylphenidate hydrochloride) prolonged-release tablets
This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-XAG-20 Date of preparation: July 2021
Steglatro®▼ (Ertugliflozin)
This formulary decision guide was developed from content provided by MSD UK Ltd in a format developed by Guidelines in Practice.
Prescribing Information (Great Britain) & (Northern Ireland), and Adverse Event Reporting Information
GB-STE-00433 | June 2021
Trurapi▼ (insulin aspart 100 units/ml)
This formulary decision guide was developed from content provided by Sanofi Ltd in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
MAT-GB-2101070(v2.0) | Date of preparation: July 2021
Identification and management of colitis in primary care—practical tips and considerations
This supplement has been commissioned and funded by Ferring Pharmaceuticals and developed in partnership with Guidelines in Practice.
View prescribing and adverse event reporting information for Cortiment® (budesonide) and Pentasa® (mesalazine)
UK-GAS-2100137 December 2021
Overcoming challenges in managing obesity in primary care
Information intended for UK healthcare professionals only. This supplement has been funded through an arm’s-length sponsorship by Novo Nordisk Limited. Guidelines in Practice approached Novo Nordisk Limited to fund the production of the supplement.
Date of preparation: December 2021
NICE atrial fibrillation: diagnosis and management guideline (NG196) update—treatment considerations for direct-acting oral anticoagulants (DOACs)
Information intended for UK healthcare professionals only. This round-table discussion supplement has been commissioned and funded by Bayer plc and developed in partnership with Guidelines in Practice.
View Xarelto®▼ (rivaroxaban) adverse event reporting and prescribing information
PP-XAR-GB-2369
Date of preparation: November 2021
Exploring decisions surrounding the optimisation of Androgen Deprivation Therapy (ADT) use for appropriate prostate cancer (PCa) patients in the NHS in light of COVID-19
Information intended for UK healthcare professionals only. This promotional supplement has been commissioned and funded by Ipsen UK Ltd and developed in partnership with Guidelines in Practice.
View DECAPEPTYL® SR (triptorelin) 3mg, DECAPEPTYL® SR (triptorelin) 11.25mg and DECAPEPTYL® SR (triptorelin) 22.5mg prescribing information and adverse event reporting information here
TRI-UK-004677
Date of preparation: October 2021
The unrecognised epidemic of vitamin D deficiency in Black, Asian and Minority Ethnic (BAME) groups: a consensus document
Information intended for UK healthcare professionals only. This supplement has been commissioned and funded by STADA incorporating Thornton & Ross, who provided the content.
TR-088d Date of preparation: August 2021
Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes
This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd
Methofill® (methotrexate) SelfDose for the treatment of adult patients with rheumatoid arthritis, Crohn’s disease, and psoriasis*
Intended for UK Healthcare professionals only.
This promotional supplement has been commissioned and funded by Accord-UK Ltd and developed in partnership with Guidelines in Practice.
Click here for Methofill® (methotrexate) prescribing information and adverse event reporting
For full indications, please consult the summary of product characteristics.
UK-03037 | Date of preparation: May 2021
Real-world usage study and survey of oral bowel cleansing for colonoscopy in Dudley, UK
This supplement has been commissioned by Norgine Pharmaceuticals Limited and contains promotional information. Information for healthcare professionals only.
Click here for PLENVU® (macrogol 3350, sodium ascorbate, ascorbic acid, sodium sulfate anhydrous, potassium chloride, sodium chloride) Prescribing and Adverse Event Reporting.
Click here for MOVIPREP® ((macrogol 3350, sodium sulfate anhydrous, ascorbic acid, sodium ascorbate, sodium chloride, and potassium chloride) Prescribing and Adverse Event Reporting.
Click here for KLEAN-PREP (macrogol 3350, anhydrous sodium sulfate, sodium bicarbonate, sodium chloride, potassium chloride) Prescribing and Adverse Event Reporting.
UK-GE-PLV-2000027
Date of preparation: February 2021
Recommending emollients for patients with atopic dermatitis or dry skin conditions
This supplement has been commissioned and funded by L’Oréal (UK) Limited and developed in partnership with Guidelines.
Date of preparation: January 2021
Showcasing local best practice in diabetes
This Guidelines in Practice supplement aims to showcase local best practice in the diagnosis and management of diabetes. The supplement includes articles from three local initiatives that have developed their own guidance or demonstrated improvements in different areas of diabetes care:
Identification and management of patients with malnutrition
This supplement has been commissioned and funded by Alliance Pharmaceuticals Ltd and developed in partnership with Guidelines in Practice.
Guideline for the managed introduction of biosimilar basal insulin
This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.
Implementing the NICE guideline on the management of acne vulgaris
Information intended for UK healthcare professionals only.
Checklist on the implementation of the NICE guideline on atrial fibrillation: diagnosis and management
This implementation checklist has been commissioned and funded by Daiichi Sankyo UK and developed in partnership with Guidelines in Practice.
View LIXIANA (edoxaban) prescribing and adverse event reporting information
EDX/21/0535 July 2021
Implementing the Guidelines algorithm on managing obesity in primary care
Guidelines in Practice approached Novo Nordisk Ltd for an educational grant to support the production of an implementation checklist. Information intended for UK healthcare professionals only.
Date of preparation: January 2021
Empagliflozin (Jardiance®) 10mg film-coated tablets SMC2396
The production of this Guidelines summary card has been commissioned by the Boehringer Ingelheim and Lilly Alliance.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain and Northern Ireland.
PC-GB-105815 October 2021
Romosozumab▼ (Evenity®) 105mg solution for injection in prefilled pen SMC2280
The production of this Guidelines card has been commissioned by UCB Pharma Ltd.
Amgen and UCB Pharma Ltd are co-developing Evenity®.
View prescribing information and adverse event reporting
UK-P-RM-OP-2000095 December 2020
View TARGAXAN ® (rifaximin-α) prescribing and adverse events reporting information
UK-HEP-XIF-2100027 Date of preparation: October 2021
Best practice in hepatic encephalopathy
Consensus statement: identification and management of hepatic encephalopathy
- Previous
- Next